Low-value practices in oncology contributing to financial toxicity. - Wikidata - wikimedia - TriplyDB

Low-value practices in oncology contributing to financial toxicity.

Low-value practices in oncology contributing to financial toxicity.

http://www.wikidata.org/entity/Q37720714

about

Cancer drugs in LMICs: cheap but unaffordable.Does the oncology community have a rejection bias when it comes to repurposed drugs?Cancer treatment in the last 6 months of life: when inaction can outperform action.

P2860

Q45362505-03055885-B26F-4507-819E-1ABC3965CA8E Q49884530-7CC12AF9-BCD6-4E32-8024-58A4EDA5A0BC Q55102136-CC79C652-A6C3-4862-B300-0D97DA63EB19

P2860

Low-value practices in oncology contributing to financial toxicity.

http://www.wikidata.org/entity/Q37720714

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 March 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Low-value practices in oncology contributing to financial toxicity.

@en

Low-value practices in oncology contributing to financial toxicity.

@nl

type

label

Low-value practices in oncology contributing to financial toxicity.

@en

Low-value practices in oncology contributing to financial toxicity.

@nl

prefLabel

Low-value practices in oncology contributing to financial toxicity.

@en

Low-value practices in oncology contributing to financial toxicity.

@nl

P1433

Q37720714-625013CA-23DF-4CCE-85E4-360FF0057B70

P1476

Q37720714-26EE42C4-D26C-4AF7-B770-61A321BCAE6A

P2093

Q37720714-20A9A368-DC11-4119-9128-D16C5AEBCE88

P2860

Q37720714-07DA1E56-56FF-477A-BECD-17D4BEC408DC

Q37720714-2271BC61-B9C6-46E8-BDDC-8054AD2B0EE7

Q37720714-2A571A6B-8A49-44D8-AAE3-00D8182AFA68

Q37720714-2C4E28FC-B118-4AE4-BAB2-584820F7982B

Q37720714-386CF505-38D1-4665-B06C-CD9491306DD0

Q37720714-3C21375C-E3B8-4A28-ADDA-9EB984B1D691

Q37720714-3DFD458E-EFB1-4677-A00F-A993F0403D87

Q37720714-45B3ECC6-ECDA-44B1-ACFF-F2D9BAC2ACBE

Q37720714-49CF5861-5624-4B73-AF30-FA97CD0FD616

Q37720714-4A644BA6-AF09-4B91-9518-C36F70572B76

P304

Q37720714-8620F06B-EBEF-40F1-B8C6-20733D65A9B0

P31

Q37720714-45F6F869-47B8-41AA-903F-3DF3202C6FD2

P356

Q37720714-7256ACC4-0E80-4AAA-9F80-B5E2EF3BB5D3

P478

Q37720714-B2EBF74F-477E-4C65-B239-5216D61175CE

P50

Q37720714-290C8952-17B1-4F53-B255-6326F452F052

P577

Q37720714-C8BC25B6-DA54-4C0A-9CB0-7D2A43BC1D7B

P698

Q37720714-3C06B1BB-59F3-4D78-B1E3-4390EF965DBA

P932

Q37720714-F3BC773B-D4B4-4FFC-9F1F-B3815710370C

P356

ECANCER.2017.727

P1433

Ecancermedicalscience

P1476

Low-value practices in oncology contributing to financial toxicity.

@en

P2093

Bishal Gyawali

http://www.w3.org/2001/XMLSchema#string

P2860

Colony-stimulating factors for chemotherapy-induced febrile neutropenia

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

Understanding provision of chemotherapy to patients with end stage cancer: qualitative interview study

Chemotherapy Use, Performance Status, and Quality of Life at the End of Life

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer.

P304

727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3332/ECANCER.2017.727

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28386297

http://www.w3.org/2001/XMLSchema#string

P932

5365336

http://www.w3.org/2001/XMLSchema#string